2021
DOI: 10.1016/j.scib.2021.07.033
|View full text |Cite
|
Sign up to set email alerts
|

Inactivated SARS-CoV-2 vaccine does not influence the profile of prothrombotic antibody nor increase the risk of thrombosis in a prospective Chinese cohort

Abstract: Graphical abstract

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

4
37
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 32 publications
(41 citation statements)
references
References 40 publications
4
37
0
Order By: Relevance
“…Vaccines that use inactivated SARS-CoV2 (currently Sinopharm [104] and Sinovac [105]) would have an intermediate incidence of complications because inactivated viruses can still fuse cells from without (Figure 2), although without the capacity to express spike the incidence of syncytia is limited by the number of injected viral particles. This prediction is consistent with safety reports for vaccines that use inactivated virus [106,107] but further studies, and having all current and future vaccines tracked by publicly accessible databases of suspected vaccine complications, like VAERS [108] in the United States and EudraVigilance [109] in Europe, would provide a larger set of data to evaluate, as has been done to compare the AstraZeneca and Pfizer vaccines [83].…”
Section: Could This Fusion Be Pathogenic?supporting
confidence: 76%
“…Vaccines that use inactivated SARS-CoV2 (currently Sinopharm [104] and Sinovac [105]) would have an intermediate incidence of complications because inactivated viruses can still fuse cells from without (Figure 2), although without the capacity to express spike the incidence of syncytia is limited by the number of injected viral particles. This prediction is consistent with safety reports for vaccines that use inactivated virus [106,107] but further studies, and having all current and future vaccines tracked by publicly accessible databases of suspected vaccine complications, like VAERS [108] in the United States and EudraVigilance [109] in Europe, would provide a larger set of data to evaluate, as has been done to compare the AstraZeneca and Pfizer vaccines [83].…”
Section: Could This Fusion Be Pathogenic?supporting
confidence: 76%
“…2), although without the capacity to express spike the incidence of syncytia is limited by the number of injected viral particles. This prediction is consistent with safety reports for vaccines that use inactivated virus 106,107 but further studies, and having all current and future vaccines tracked by publicly accessible databases of suspected vaccine complications, like VAERS 108 in the United States and EudraVigilance 109 in Europe, would provide a larger set of data to evaluate, as has been done to compare the AstraZeneca and Pfizer vaccines 83 .…”
Section: Could This Fusion Be Pathogenic?supporting
confidence: 75%
“…Therefore, the benefits of administering inactivated--virus vaccines against SARS--CoV--2 to elite strength, power and endurance athletes include, but are not limited to: 1) the formation of a robust and enduring antibody response against the comprehensive landscape of SARS--CoV--2 antigenic epitopes (55,56,57,65,67,68,69,70) 2) no requirement for elite athletes to reduce scheduled physical training and/or competitions following immunization (since exercise functions as a well recognized adjuvant to vaccination with an inactivated--virus vaccine 40,41,42,43); and there is no increased mechanistic risk of thrombogenesis and/or thromboembolism incurred by populations of actively training elite athletes following vaccination with an inactivated--virus SARS--CoV--2 vaccine (56). The maintenance of low levels of isolated spike proteins and/or isolated S1 following vaccination of elite athletes against SARS--CoV--2 are crucially important, due to the fact that actively training elite athletes are inherently predisposed to an elevated exercise--induced risk of thrombogenesis and thromboembolism, and isolated spike protein and/or isolated S1 acts to dramatically enhance this risk by facilitating coagulation and thrombogenesis in the context of exercise--induced elevations of plasma ADP (4,44,128,132).…”
Section: Emergent Properties Arising From the Intersection Of Sars-cov-2 Spike Protein Toxicity Sars-cov-2 Vaccination Technology And Thementioning
confidence: 99%
“…That those members of the population who possess the most proficient protein synthetic apparatus frequently suffer pathology secondary to the toxicity of vaccine--induced, self-generated spike proteins and/or spike protein constituent components, such as S1, should not be viewed as rare, nor unexpected occurrences, but rather, an increased mechanistic risk for thrombosis and/or myocarditis should be fully recognized as an entirely logical and expected outcome issuing forth from the application of vaccination technology that is capable of flogging the protein synthetic apparatus of recipient patients, in a non--throttleable manner so as to generate very high rates of seroconversion amongst even the most catabolic segments of the population, exemplified, as such, by patients with end--stage renal disease (91). The significantly increased mechanistic risk incurred by populations of elite strength, power and endurance athletes upon vaccination with SARS--CoV--2 nucleotide vaccines provides a stark contrast to the impressively benign risk: reward ratio afforded to populations of elite athletes by inactivated--virus vaccines (37,39,47,56,100,135). The desirable risk profile of inactivated--virus SARS--CoV--2 vaccines in populations, such as elite athletes, with highly competent protein synthetic apparatus, expanded skeletal muscle capillary networks and high levels of physical activity are exemplified by the fact that individuals receiving inactivated--virus vaccines against SARS--CoV--2 are devoid of injuries and deaths resulting from myocarditis and thrombosis (56).…”
Section: Emergent Properties Arising From the Intersection Of Sars-cov-2 Spike Protein Toxicity Sars-cov-2 Vaccination Technology And Thementioning
confidence: 99%
See 1 more Smart Citation